Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

por Péron, J, Roy, P, Ding, K, Parulekar, W R, Roche, L, Buyse, M
Publicado 2015

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

por Parulekar, W.R., McKenzie, M., Chi, K.N., Klotz, L., Catton, C., Brundage, M., Ding, K., Hiltz, A., Meyer, R., Saad, F.
Publicado 2008